ArticleAntimicrobial resistance and infection control2019
Characteristics of
Article in Antimicrobial resistance and infection control, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Antibiotic resistance in Helicobacter pylori among children and adolescents in East Asia: A systematic review and meta-analysis.Chinese medical journal · 2024Pooled it
- The prevalence of clarithromycin-resistantPeerJ · 2023Pooled it
- Effectiveness and safety of vonoprazan and amoxicillin dual regimen with Saccharomyces boulardii supplements on eradication of Helicobacter pylori.BMC gastroenterology · 2024Trial
- Fourteen-day vonoprazan and low- or high-dose amoxicillin dual therapy for eradicatingFrontiers in immunology · 2022Trial
- Application of a semi-automatic, intensive follow-up for improving efficacy and adherence of Helicobacter pylori eradication therapy: A randomized controlled trial.MicrobiologyOpen · 2021Trial
- Identifying the best regimen for primary eradication of Helicobacter pylori: analysis of 240 cases.MicrobiologyOpen · 2020Trial
- Burden, clinical impact, and primary antimicrobial resistance profiles of Helicobacter pylori infections in Cameroon: A systematic review and meta-analysis.PLOS global public health · 2026Article
- Patchouli alcohol suppressesFrontiers in pharmacology · 2026Article
- Helicobacter pylori antimicrobial resistance and gene variants in Shandong Province.Scientific reports · 2025Article
- Connection of vitamin D levels in blood serum withPrzeglad gastroenterologiczny · 2025Article
- Success of susceptibility-guided eradication ofWorld journal of gastroenterology · 2024Article
- Article
- Antibiotic-Resistant Strains of Helicobacter pylori in 50 Antibiotic Treatment-Naive Children in Northeast Poland Diagnosed by Gastric or Duodenal Biopsy Between February 2019 and May 2022.Medical science monitor : international medical journal of experimental and clinical research · 2023Article
- Current Worldwide Trends in PediatricChildren (Basel, Switzerland) · 2023Review
- EmpiricalTherapeutic advances in gastroenterology · 2023Article
- Article
- A Comparison of Doxycycline and Amoxicillin Containing Quadruple Eradication Therapy for TreatingPathogens (Basel, Switzerland) · 2022Article
- Primary Antibiotic Resistance ofPathogens (Basel, Switzerland) · 2022Review
- Current guidelines forWorld journal of clinical cases · 2022Review
- A Survey ofAntimicrobial agents and chemotherapy · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: To describe the characteristics of Methods: In total, 1463 Results: In the treatment-naïve adult group, the resistance rates for metronidazole, clarithromycin, levofloxacin, amoxicillin, rifampicin and tetracycline were 78.4, 19.0, 23.3, 1.2, 1.7 and 2.3%, respectively. Compared with this group, the previously treated adult group had significantly higher resistance rates for metronidazole (99.2%), clarithromycin (58.3%) and levofloxacin (52.3%). In addition, the treatment-naïve children had a lower metronidazole resistance rate (46.0%) than the treatment-naïve adults. The resistance rate for clarithromycin was low in treatment-naïve patients with ages ranging from 10 to 24 years. For the strains isolated from the general population group, the resistance rates for metronidazole, clarithromycin, levofloxacin, amoxicillin, rifampicin and tetracycline were 78.6, 10.1, 25.1, 0.5, 2.1 and 0.9%, respectively. Compared with the treatment-naïve adult group, the general population group showed significant differences in clarithromycin resistance. Conclusion: The resistance rates for metronidazole, clarithromycin and levofloxacin were high, especially in previously treated adults. Compared to those in treatment-naïve younger patients, the resistance rates for clarithromycin were significantly lower in treatment-naïve patients with ages ranging from 10 to 24 years and in the general population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.